Mechanical Characterisation of Nucleic Acids using Single Molecule Methods (MeCHaNiSM)
Forskningsprojekt, 2024
– 2028
Nucleic acid (NAs)-based therapies have started to yield major advances in the treatment of human disease. New approaches for understanding NA structure and function are required to extend the boundaries of today’s gene editing technologies, cancer therapies, and mRNA vaccines. Single-molecule techniques have revolutionised our understanding of NAs and their interactions with therapeutic oligonucleotides, small molecules, and proteins.
However, for Europe to remain competitive in this area, new expertise is urgently required in single-molecule NA analysis, which intersects the fields of physical chemistry, biophysics, NA synthesis, and computation. MeChaNiSM will train the next generation of European scientific leaders in the development and use of single-molecule biophysics techniques where they will investigate critical interrelated question regarding the structure, dynamics, function, and interactions of NAs. To do this, our Doctoral Candidates (DCs) will:
- Unravel high-resolution NA structures and intramolecular forces with modified bases
- Understand the conformation and dynamics of NAs at the single-molecule level
- Develop next-generation therapeutics for treating genetic diseases
MeChaNiSM connects world-leading researchers working in the fields of single-molecule biophysics, NA chemistry, and computational modeling with outstanding industrial partners working in complementary fields.
In addition to conducting world-class research, our DCs will understand industrial needs, have know-how in running multidisciplinary research, and will be immersed in a broad collaborative network connecting academia and industry. Our DCs will provide vital future breakthrough applications in NAs and single-molecule analysis to pharmaceutical and biotechnological industries where the design of new drugs - including NA-based therapeutics and vaccine technologies - will provide major improvements to human health.
Deltagare
Fredrik Westerlund (kontakt)
Chalmers, Life sciences, Kemisk biologi
Marcus Wilhelmsson
Chalmers, Kemi och kemiteknik, Kemi och biokemi
Samarbetspartners
AstraZeneca AB
Södertälje, Sweden
Dublin City University
Dublin, Ireland
KU Leuven
Leuven, Belgium
LUMICKS BV
Amsterdam, Netherlands
NanoTemper Technologies GmbH
Munchen, Germany
National Institute for Bioprocessing Research and Training (NIBRT)
Dublin, Ireland
Stichting VU-VUmc
Amsterdam, Netherlands
Universitat de Barcelona
Barcelona, Spain
Universiteit Utrecht
Utrecht, Netherlands
Universiteit Van Amsterdam
Amsterdam, Netherlands
Universität zu Köln
Köln, Germany
Finansiering
Europeiska kommissionen (EU)
Projekt-id: EC/HE/101168851
Finansierar Chalmers deltagande under 2024–2028